MEDIFAST INC — Form 8-K
Filed August 3, 2026 · analyzed by the 8-K Agent
8-K
▼ Likely negative
significance 72/100
What the filing says
Medifast reported Q2 2026 revenue of $76.4M (down 27.6% YoY from $105.6M) with active earning coaches plummeting 48.7% to 11,700 from 22,800. The company posted a net loss of $3.1M ($0.28 per diluted share) versus $2.5M net income in Q2 2025. CEO cited turnaround signs and expects profitability in Q4 2026; however, full-year 2026 guidance remains weak at $270M–$300M revenue and $(0.25)–$(1.75) EPS.
Why this rating
Revenue collapse and massive coach attrition represent acute business stress; $76.4M quarterly run-rate is ~52% of market cap. GLP-1 competition cited. Balance sheet strong ($169.8M cash, no debt) cushions near-term runway, but profitability recovery unproven.
See more from August 3, 2026.
EDGAR·FLOW summarizes public SEC EDGAR filings with automated analysis. Materiality scores and stock-impact predictions are algorithmically generated and are not investment advice. Always verify against the source filing on SEC.gov.